MedTrace Logo

Rituximab in Systemic Sclerosis

NCT01748084 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2025-11-20

No results posted yet for this study

Summary

The purpose of this study is to determine whether rituximab is effective in the treatment of articular symptoms that occur in systemic sclerosis related polyarthritis

Conditions

Interventions

DRUG

Rituximab

Days 1 and 15, rituximab 1 gramme plus 100 mg methylprednisolone

DRUG

Placebo (NaCl)

Days 1 and 15, NaCl 500 ml plus 100 mg methylprednisolone

Sponsors & Collaborators

  • URC-CIC Paris Descartes Necker Cochin

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Yannick Allanore, MD, PhD · Assistance Publique Hôpitaux de Paris, Université Paris Descartes

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-09
Primary Completion
2016-04-18
Completion
2016-04-18

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01748084 on ClinicalTrials.gov